Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
The Pharma Data
AUGUST 3, 2021
The company confirmed the tirzepatide SURPASS program has met global regulatory submission requirements for evaluating cardiovascular risk and its intention to submit the registration package to regulatory authorities by the end of 2021. 25% $ 2,988.1 $ 2,459.1 22% Humalog ®(a) 607.6 2)% Alimta 610.6 6% Taltz 569.1 26% Humulin ® 315.3
Let's personalize your content